Enfusion, Inc. (NYSE:ENFN) CTO Dan Groman Sells 5,000 Shares

Enfusion, Inc. (NYSE:ENFN) CTO Dan Groman sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $9.97, for a total transaction of $49,850.00. Following the completion of the sale, the chief technology officer now owns 133,828 shares in the company, valued at $1,334,265.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Dan Groman also recently made the following trade(s):

• On Tuesday, October 17th, Dan Groman sold 5,000 shares of Enfusion stock. The shares were sold at an average price of $9.09, for a total transaction of $45,450.00.
• On Tuesday, September 19th, Dan Groman sold 5,000 shares of Enfusion stock. The shares were sold at an average price of $9.07, for a total value of $45,350.00.

Enfusion Price Performance

ENFN opened at $10.11 on Friday. The business has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.09. Enfusion, Inc. has a 12 month low of $7.37 and a 12 month high of $13.06. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 126.39, a PEG ratio of 2.38 and a beta of 0.81.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group began coverage on Enfusion in a research note on Tuesday, November 7th. They issued a “neutral” rating and a $9.00 price objective for the company. The Goldman Sachs Group dropped their target price on Enfusion from $11.50 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Finally, Morgan Stanley reduced their price target on shares of Enfusion from $12.00 to $11.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and an average price target of $10.17.

Hedge Funds Weigh In On Enfusion

Several hedge funds and other institutional investors have recently made changes to their positions in ENFN. Envestnet Asset Management Inc. acquired a new position in Enfusion during the 1st quarter worth approximately $128,000. Bank of New York Mellon Corp lifted its position in shares of Enfusion by 1,435.5% during the 1st quarter. Bank of New York Mellon Corp now owns 762,883 shares of the company’s stock worth $9,704,000 after purchasing an additional 713,201 shares during the last quarter. Citigroup Inc. grew its stake in shares of Enfusion by 24.2% during the first quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock worth $91,000 after purchasing an additional 1,390 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Enfusion by 55.4% in the first quarter. MetLife Investment Management LLC now owns 14,206 shares of the company’s stock valued at $181,000 after buying an additional 5,065 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Enfusion by 33.6% during the 1st quarter. Rhumbline Advisers now owns 21,723 shares of the company’s stock worth $276,000 after buying an additional 5,468 shares during the last quarter. Hedge funds and other institutional investors own 64.43% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.